ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (1) , 60-66
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI (CA128914)
- NIH/NCRR/RCMI (G12RR03062)
This publication has 26 references indexed in Scilit:
- Id4 dependent acetylation restores mutant-p53 transcriptional activityMolecular Cancer, 2013
- Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTENMolecular Cancer, 2013
- Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1BCancer Medicine, 2012
- Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancerCancer Medicine, 2012
- Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosisBiochemical and Biophysical Research Communications, 2012
- Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancerBMC Cancer, 2009
- Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancersNucleic Acids Research, 2009
- Androgen receptor is a tumor suppressor and proliferator in prostate cancerProceedings of the National Academy of Sciences, 2008
- PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptorThe Prostate, 2006
- DU‐145 and PC‐3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulationFEBS Letters, 2006